Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing precision oncology therapies focused on solid tumors to preserve organ function. Its lead product candidate, belzupacap sarotalocan (bel-sar), is a virus-like drug conjugate designed for targeted, light-activated tumor cell killing and immune activation. Aura targets ocular and urologic cancers, including choroidal melanoma and bladder cancer, aiming to offer vision- and organ-sparing treatments with potential long-term antitumor immunity.
This description was generated via AI from an annual report. Updated about 1 year ago.